INTRODUCTION
Most of the successes in the development of antivirals active against herpes viruses have been achieved with synthetic nucleoside analogues. It is well known that a synthetic chemotherapeutic agent, acyclovir, studied by Elion et al. 1, 2) , (awarded the Nobel Prize in the field of Physiology or Medicine, 1988) , is the best medicine for herpes virus infections. Acyclovir has virus-specific activation in virus-infected cells and its activated form inhibits viral DNA replication through obligate chain termination. The remarkable characteristic of acyclovir is its lack of effect on uninfected cells. This lack of cytotoxicity has subsequently translated into an outstanding safety profile in the clinic. Over the past 20 years acyclovir has become the drug of choice for the treatment and suppression of herpes infections.
Why could microorganisms including actinomycetes not produce the valuable antiviral antibiotics? Recently, new antiviral agents produced by actinomycetes, which are effective for herpes virus or human immunodeficiency virus, have been found: cycloviracins B 1 and B 2 , and fattiviracins having the macrocyclic dilactones formed by the binding of two trihydroxy fatty acids and two D-glucose residues in the molecules.
The author will introduce the antiviral antibiotics, mainly fattiviracins, that were isolated and studied in our laboratories.
Cycloviracins 3-5)
The cycloviracin-producing strain, Kibdelosporangium albatum No. R761-7 (ATCC 55061), was isolated from a soil sample collected in Mindanao Island, the Philippines. A complex of new antibiotics was extracted from the fermentation broth with 1-butanol, and purified by column chromatographies on silica gel, reversed phase C 18 , preparative HPLC and Sephadex LH-20. Two major components, cycloviracins B 1 and B 2 , have been isolated from the complex. They were soluble in methanol, pyridine and dimethyl sulfoxide, slightly soluble in ethyl acetate and acetone, but practically insoluble in n-hexane, chloroform and water. Their structures have been determined by chemical and spectroscopic methods including 2D NMR correlation spectroscopy. The antibiotics are unique macrocyclic diesters consisting of two D-glucoses, three 2-O-methyl-D-glucoses and two (C 24 and C 26 ) hydroxy fatty acids (Fig. 1) .
Antiviral activity of cycloviracins B 1 and B 2 was evaluated by the dye uptake 6) and the plaque reduction assay 7) using herpes simplex virus type 1 (HSV-1) (KOS strain) infection in Vero cells (a cell line of kidney from African green monkey). In the dye uptake assay, 200 µl of the Vero cell suspension containing 1.6 × 10 4 cells was poured into each well of 96-well microplates, and then 50 µl of a medium containing a test compound at various concentrations was added to each well. The viral suspension (50 µl) containing approximately 30 × TCID 50 was inoculated at 37°C for 72 hr under a 5% CO 2 in humidified air environ- Fattiviracins HSV-1 causes a wide spectrum of acute and recurrent diseases in humans. Although acyclovir (ACV), an excellent synthetic antiherpetic agent, is now in clinical use for the treatment of herpes diseases, the appearance of ACVresistant mutants is thought to be a serious problem.
In order to search for novel antiherpetic agents in place of ACV, we have screened antiherpetic agents produced by soil microorganisms, especially actinomycetes strains, using a rapid method for detection of antiherpetic agents using 96-well microtiter plates by plaque reduction assay 7) . Of the approximately 2,500 actinomycetes strains tested, four new antiherpetic agents were found in our laboratories: AH-135Y (Fig. 2) (a new glutarimide antibiotic) produced by Streptomyces albovinaceus strain No. 135 8) , AH-758 ( Fig. 3 ) (a new macrolide antibiotic belonging to bafilomycin 9) ) produced by Streptomyces rochei strain No. 758 10) , AH-1763IIa (Fig. 4) (a new antibiotic belonging to the pluramycin group 11) ) produced by Streptomyces cyaneus strain No. 1763 12) and fattiviracins (new antibiotics belonging to sugar-fatty acid lactone) produced by Streptomyces microflavus strain No. 2445 [13] [14] [15] [16] [17] . AH-135Y showed an antiherpetic activity of 2.1 µg/ml as EC 50 against HSV-1, and cytotoxicity of 30.0 µg/ml as IC 50 against Vero cells, and therefore the selective index (ratio of IC 50 to EC 50 ) was estimated as 14.3. AH-135Y was also effective on influenza A virus and respiratory syncytial virus (RS virus).
AH-758 showed an antiherpetic activity of 0.09 µg/ml as EC 50 against HSV-1, and cytotoxicity of 1.3 µg/ml as IC 50 against Vero cells and therefore the selective index was estimated as 14.4. The EC 50 against cytomegalovirus was less than 0.5 ng/ml, so AH-758 shows promise as an agent to fight cytomegalovirus infection.
AH-1763 IIa showed an antiherpetic activity of 2.1 µg/ml as EC 50 against HSV-1, and cytotoxicity of 15.2 µg/ml as IC 50 against Vero cells and therefore the selective index was estimated as 7.2.
Thirteen additional compounds were purified, but they were found to be known antibiotics.
Isolation and Purification of Fattiviracins

13, 15)
In 1995, we discovered new antiherpetic agents, called fattiviracins. The producing strain No. 2445 was isolated from a soil sample collected at a riverside of River Tuboi in Kumamoto, Japan. The characterization and identification of this strain were carried out mainly according to Bergey's Manual of Systematic Bacteriology 18) and the International Streptomyces Project (ISP) report 19) . From its cultural and taxonomic characteristics, this strain was classified as a strain belonging to Streptomyces microflavus. Therefore, it is called Streptomyces microflavus strain No. 2445 hereafter. The culture has been deposited to the National Institute of Bioscience and Human-Technology in the Agency of Industrial Science and Technology under the accession No. FERM P-16524.
Fermentation was carried out at 28 °C for 96 h, and the filtrate was used to isolate fattiviracins. This strain turned out to produce at least 13 fattiviracin derivatives (FV-1 to FV-13). Fattiviracins were purified through column chromatographies on Diaion HP-10, silica gel, ODS and preparative HPLC using a reverse phase column. All the purification steps were monitored by measuring the inhibitory activity of plaque formation by HSV-1. Fattiviracins were obtained as a white amorphous powder. Its crystallization trial is now carried out for X-ray analysis of the structure. They were readily soluble in water, methanol, pyridine and dimethyl sulfoxide, but insoluble in n-hexane, chloroform, ethyl acetate and acetone. The structures of fattiviracins were determined by several spectroscopic analyses and chemical degradations. Ten derivatives, except fattiviracins FV-1 to FV-3, belonged to sugar-fatty acid lactone. Fattiviracins FV-1 to FV-3 remain undetermined because only trace amounts were available. As shown in Fig. 5 , fattiviracins have macrocyclic diesters formed by the binding of two trihydroxy fatty acids and two D-glucose residues in the molecules, and they can be divided into 5 families according to the length of fatty acid moiety. Some of them will be stereoisomer to each other. They are closely related to cycloviracins B 1 and B 2 , but differ from these known compounds in both the length of their side chain and the sugar moiety. Cycloviracins have three 2-O-methyl-D-glucoses bound to two hydroxy fatty acids as described above. On the other hand, fattiviracins have two normal glucoses bound to the same acids. Fattiviracins show almost the same antiviral activity against HSV-1 (EC 50 = 2.5 -3.1 µg/ml) regardless of the length of their fatty acid chains.
Antiviral Spectra
16)
Antiviral spectra against various viruses were examined with fattiviracin FV-8 ( Table 1 ). The antiviral activities of FV-8 on HSV-1, VZV, influenza and polio viruses were measured by a plaque reduction assay. Briefly, confluent monolayers of Vero or MDCK (canine kidney) cells in 6-well plates were infected with 100 PFU (plaque-forming unit) of each virus. After a 1-hr adsorption period, the cultures were overlaid with Dulbecco's modified Eagle's minimum essential medium (DMEM) containing 2% heatinactivated fetal calf serum (FCS) (Gibco BRL), including various concentrations of FV-8. The plates were incubated in a CO 2 incubator for 3 days, then fixed with formalin and stained with crystal violet in methanol. Infectious virus production was measured by counting plaques caused by virus-induced cytopathic effects. The toxicities to the host cells were examined by means of the uptake of crystal violet 20) . The antiviral activity of FV-8 on HIV-1 was tested by MAGI (multinuclear activation of a galactosidase indicator) assay 21) . MAGI/CCR5 cells (3 × 10 5 cells) were infected with three types of HIV-1 (IIIB/T-, JR-FL/M-, or 89.6/dual-tropic strains) and incubated for 2 days in a growth medium (10% FCS + RPMI 1640) containing different concentrations of FV-8. Individual infected cells were counted in situ with a light microscope by virtue of their blue color after incubation with 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal).
FV-8 had a similar antiviral activity against IIIB, JR-FL, and 89.6 strains of HIV-1 regardless of the cell tropism of HIV-1, and these EC 50 ′s were 4.3, 3.5, and 6.1 µg/ml, respectively. The antiviral activities of FV-8 had antiviral EC 50 ′s of 2.7, 3.0, 1.9, and 3.3 µg/ml against HSV-1, VZV, influenza A virus and influenza B virus, respectively. FV-8 has a potent activity against enveloped DNA viruses of the herpes family, HSV-1 and VZV, and enveloped RNA viruses of influenza A virus, influenza B virus, and three strains of HIV-1. However, it showed no antiviral activity against the unenveloped RNA virus of the polio virus, even at the concentration of 1 mg/ml. It has no cytotoxicity against Vero cells even at a concentration of 5 mg/ml. Therefore the selective index of FV-8 against HSV-1 was estimated as over 1852, which exhibits excellent selectivity compared to the selective index 850 of the antiherpetic agent, ACV. In addition, the low toxicity is expected to be very potent for the application.
Mechanism of antiviral action
16)
The effects of FV-8 treatment time on HIV-1 infection were examined, and are shown in Fig. 6 . In the addition just before viral infection, FV-8 showed strong antiviral activity (EC 50 =4.3 µg/ml), but 1 hr later, the activity decreased (EC 50 =28.9 µg/ml), and no antiviral activity was observed in the addition 3 hr after HIV-1 infection (EC 50 >100 µg/ml). These results suggested that FV-8 does not show antiviral activity against the HIV-1 that has already invaded host cells, that is, the agent acts on HIV-1 particles directly before infection.
To examine the effects of FV-8 on HIV-1 particles, IIIB strain was treated with different concentrations of FV-8 for 30 min at 37 °C. After ultracentrifugation (60,000 rpm, 60 min), the precipitate (viral fraction) was suspended in a growth medium and infected to MAGI/CCR5 cells. The lysis of the viral envelope and capsid of HIV-1 particles was estimated on the basis of the amount of p24 in the viral fraction measured by HIV-1 p24 capsid enzymelinked immunosorbent assay (Abbott) 22) . The effects of FV-8 on HIV-1 particles are shown in viral entry into the host cells. The antiviral mechanism of FV-8 is clearly different from those of zidovudine 23) and ritonavir 24) , the antiviral activities of which are inhibitions of reverse transcriptase and protease in the HIV-1 particles, respectively.
In recent studies, it was found that FV-8 did not interact with gp120 binding with CD4 on the surface of a host cell, but did interact with trans-membrane gp41 connecting with the gp120.
Biosynthesis of fattiviracin 17)
Fattiviracins have four glucoses in the molecule. To examine the incorporation of glucose into the FV-8 molecule, [1- 13 C] D-glucose was fed into the culture medium. Labeled FV-8 was isolated and its 13 C NMR spectrum was examined to identify the carbon enrichment. As shown in Table 2 , 13 C incorporation was observed at each of the carbon numbers 25, 23′, 1A and 1B, which correspond to the 1-carbon of four glucose residues in the FV-8 molecule. The results suggest that the strain has the ability to directly incorporate glucose in the culture medium into the FV-8 molecule.
For the production of the modified FV-8′s consisting of various sugar residues, several types of sugar, such as galactose, mannose, fructose, xylose, and arabinose were used in place of glucose in the medium No. 4 consisting of glucose 5.0%, corn steep liquor 1.0%, peptone 0.5%, NaCl 0.3%, CaCO 3 0.3% (pH 7.0). Then, each modified FV-8 was purified from respective culture filtrates and degraded with HCl to identify the sugar residues. The antiherpetic activity and sugar residues of each modified FV-8 were examined and are summarized in Table 3 . The modified FV-8′s showed almost the same antiherpetic activity, and the sugar residues in these molecules were all found to be glucoses. Also, the structures of the modified FV-8′s were identified as an original FV-8 from the NMR and mass spectral data. In addition, there were no modified fattiviracins with sugars other than glucose in fattiviracin derivatives produced by the strain. These results suggest that the strain may have the ability to convert different types of sugar in the culture medium to glucose which is exclusively incorporated into the FV-8 molecule.
The conversion of pentose (xylose) to hexose (glucose) is especially interesting. To confirm this conversion, an experiment using a resting-cell system was carried out, and the result of HPLC is shown in Fig. 8 , Antiviral activity of FV-8. , Amount of p24 in the viral fraction. days incubation, a peak of glucose was detected in place of xylose. Moreover, the conversion of xylose to xylulose was verified by a cell-free extract system, as shown in Fig.  9 . After incubation for 30 min, the conversion rate of xylose to xylulose was 5%, and the conversion increased with incubation time, and after 240 min, the rate was 21.5%. Further experimentation for the conversion of xylose to glucose was done by the [1- 13 C] D-xylose feeding experiment. As shown in Table 4 , 13 C incorporation was observed at each of the carbon numbers 25, 27, 23′, 25′, 1A, 3A, 1B and 3B, which correspond to the 1, 3-carbon of four glucose residues in the FV-8 molecule. These results may be explained by the conversion of xylose to glucose through the pentose phosphate pathway 25) , as shown in Fig. 10 . It is clear that the glucose converted from xylose is incorporated into the FV-8 molecule.
The biosynthesis of the non-sugar moiety of FV-8 was examined by feeding experiments using [1- Table 5 , the 13 C NMR spectrum of labeled FV-8 indicated that the carbon atoms of the non-sugar moiety in the FV-8 molecule are derived from acetic acid, according to an expected polyketide pathway 26) .
Cerulenin is known as an inhibitor of fatty acid biosynthesis 27) through a polyketide pathway. By the addition of cerulenin to the actinomycete cultures that produce polyketide-antibiotics through the pathway, such as leucomycin of Streptomyces kitasatoensis, spiramycin of S. ambofaciens and tylosin of S. fradiae, the production of these antibiotics is inhibited without growth inhibition [28] [29] [30] . To investigate whether the biosynthesis of fatty acid residues in the fattiviracin molecule occurs through this pathway or not, cerulenin was added to the culture, and the production of FV-8 in the culture filtrate was measured. As shown in Fig. 11 , the addition of cerulenin at the onset, 24, 48 and 72 hr of cultivation, inhibited the production of FV-8 by about 70 to 96% without growth inhibition. The result indicates that the fatty acid residues in the fattiviracin molecule may be biosynthesized through the polyketide pathway 26) .
An increased production of fattiviracins by bacitracinresistant strain
31)
To obtain large quantities of the compounds efficiently, improvements in productivity and purification are required. If the producing strain produced only a few fattiviracins components, the purification procedure would be simple. In this study, we demonstrate that the Streptomyces microflavus strain No. 2445 that acquired resistance for bacitracin (BC) exhibits significant quantitative and qualitative alterations in the production of fattiviracins. method 32) using MGA agar plates consisting of glucose 1.0%, asparagine 0.05%, K 2 HPO 4 0.05%, yeast extract 0.05%, and agar 1.5%, at pH 7.0. The MIC of the wild strain to BC was 10 µg/ml. The spontaneous BC-resistant mutants of the wild strain were obtained as resistant colonies that grew within 10 days, after spores were spread on MGA agar plates containing BC. Spores generated on the MGA agar plate containing the highest concentration of BC were transferred onto MGA agar plates containing higher concentrations of BC. This cultivation was repeatedly carried out to generate BC resistance. After 5 to 6 transfers onto MGA agar plates containing the raised concentrations of BC, BC-resistant strains (BCR) designated as 40-BCR, 120-BCR and 350-BCR grown on the plates containing 40, 120 and 350 µg/ml of BC, respectively, were obtained. The spore mass color of the strain grown on MGA agar containing BC up to 20 µg/ml was observed as the same brownish gray as that of the wild strain, however, that of 40-BCR was gray, and those of BCR grown on MGA agar containing 60 to 350 µg/ml of BC turned white. The BC-resistant strains cultivated on MGA agar slants containing the same concentration of BC at 28 °C for 2 weeks were then stored at 5 °C.
Minimum inhibitory concentrations (MIC) of BC to
Comparison of the wild strain and 40-BCR with respect to fattiviracin production was carried out. The antiviral activity of the culture filtrate against HSV-1 was measured by the plaque reduction assay mentioned above. Somogyi-Nelson method 33) . As shown in Fig. 12 , the antiviral activities of the wild strain and 40-BCR were 134 and 280 unit/ml after 6 days cultivation, respectively. This showed that 40-BCR produced 2.1 times more fattiviracins than the wild strain. The mycelium growth of 40-BCR was 1.3-fold higher than that of the wild strain after 6 days cultivation (Fig. 12) . The utilization of glucose was the same for all cultures. The patterns of antiviral activity of culture filtrate and mycelium growth among 40-BCR, 120-BCR and 350-BCR were almost the same (Fig. 13) . From these results, a BC-resistant concentration of 40 µg/ml was thought to be sufficient to raise fattiviracin production.
To investigate the fattiviracin components produced by the wild strain and 40-BCR, 500 ml of the 6-day cultures were partially purified and fattiviracin components in the crude sample were analyzed with an analytical HPLC (column: µBondapak C 18 , Waters Associates, 4.6 × 150 mm, mobile phase: 90% MeOH, flow rate: 0.42 ml/min, detection: OD at 210 nm). Fig. 14 shows the different patterns of fattiviracin components. Especially, 40-BCR produced fattiviracin FV-13 exclusively, which accounted for approximately 68% of the total fattiviracin components. On the other hand, the amounts of fattiviracin FV-10 and FV-12 were lower in the 40-BCR culture. These results suggest that the fattiviracin-producing strain that acquired resistance for bacitracin has the ability to produce a higher fattiviracins and an increased FV-13 component.
The regulation of the length of fatty acid moiety in a fattiviracin molecule is important for an increased production of fattiviracins. We considered BC-resistant mutation which might regulate the membrane lipid metabolism in the fattiviracin-producing strain, would influence the production of fattiviracins. The development of fattiviracins as an antiviral drug was difficult in terms of large-scale preparation because of the low productivity and the existence of thirteen fattiviracin derivatives. However, the BCresistant strain (40-BCR) exhibits the higher antiviral activity and, in addition, more astringent productivity of fattiviracin FV-13 which has the highest molecular weight of the fattiviracin components. Large scale production of fattiviracin FV-13 is now underway with the 40-BCR. Also, the strains that acquired a resistance for higher concentrations of bacitracin (120-BCR and 350-BCR) will be studied for their strength.
The mechanism of resistance of the fattiviracin-producing strain to BC has not been studied. Bacitracin is one of the inhibitors of cell wall biosynthesis of bacteria. By binding to the C 55 -isoprenyl pyrophosphate in the presence of a divalent cation, bacitracin prevents the formation of C 55 -isoprenyl phosphate. C 55 -isoprenyl pyrophosphate functions as a lipid carrier for the transport across the membrane of the disaccharide-pentapeptide subunits of the peptidoglycan cell wall 34) (Fig. 15 ). In the bacitracin-resistant strains of Escherichia coli, Streptococcus pneumoniae and Staphylococcus aureus, when membrane-associated isoprenol kinase encoded in the bacA gene is overproduced, it is able to produce sufficient quantities of C 55 -isoprenyl phosphate from C 55 -isoprenol to overcome the effects of C 55 -isoprenyl pyrophosphate sequestration, thereby causing bacitracin resistance 35, 36) . In the bacitracin-resistant strain of Streptomyces microflavus strain No. 2445, the possibility of an increase in C 55 -isoprenyl phosphate or the activation of isoprenol kinase that may be related with the biosynthesis of fatty acid moieties in FV-13 molecule is now under investigation. , Inhibition site by antibiotics.
